Table 2.
Cox Regression Analysis on the Predictors of the Composite Outcomes in Patients With Fabry Disease Presenting With LVH
| Variables | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Clinical characteristics | ||||||
| Age | 1.10 | 1.06–1.15 | <0.001* | 1.06 | 1.01–1.11 | 0.02* |
| Men | 2.07 | 0.91–4.68 | 0.08 | 2.37 | 0.96–5.89 | 0.06 |
| BMI | 0.93 | 0.84–1.04 | 0.2 | |||
| Smoking | 1.33 | 0.53–3.35 | 0.5 | |||
| NYHA class III/IV | 12.55 | 5.03–31.27 | <0.001* | 4.61 | 1.55–13.69 | 0.006* |
| eGFR | 0.98 | 0.96–0.99 | 0.002* | 0.98 | 0.96–1.00 | 0.03* |
| Cholesterol | 0.99 | 0.98–1.00 | 0.2 | |||
| Classical type | 0.84 | 0.29–2.48 | 0.8 | |||
| IVS4+919G>A | 1.95 | 0.66–5.72 | 0.2 | |||
| Hypertension | 1.43 | 0.64–3.20 | 0.4 | |||
| Diabetes | 1.18 | 0.44–3.16 | 0.7 | |||
| Dyslipidemia | 2.32 | 1.02–5.27 | 0.04* | 0.98 | 0.34–2.84 | 1.0 |
| AF | 3.8 | 1.70–8.50 | 0.001* | 0.83 | 0.25–2.75 | 0.8 |
| Echocardiography | ||||||
| LVEF <40% | 13.07 | 2.77–61.75 | 0.001* | 1.77 | 0.32–9.92 | 0.5 |
| LV mass index | 1.01 | 1.00–1.01 | 0.003* | 1.00 | 0.99–1.01 | 0.8 |
| LA dimension | 1.06 | 1.00–1.11 | 0.05 | |||
| Average E/e′ | 1.11 | 1.05–1.17 | <0.001* | 1.02 | 0.94–1.10 | 0.7 |
| Apical aneurysm | 8.41 | 3.46–20.42 | <0.001* | 3.59 | 1.30–9.91 | 0.01* |
| CMR | ||||||
| LGE | 3.68 | 0.99–13.73 | 0.05 | |||
| Treatment | ||||||
| ERT | 0.8 | 0.34–1.86 | 0.6 | |||
AF indicates atrial fibrillation; BMI, body mass index; CMR, cardiovascular magnetic resonance; E/e', the ratio of early diastolic tansmitral inflow velocity to early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; ERT, enzyme replacement therapy; HR, hazard ratio; LA, left atrial; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; and NYHA, New York Heart Association.
*
P<0.05.